Back to discover
Disease
Anaphylaxis
Late-stage therapeutic developmentEmerging research
1
Publications
13
Clinical trials
12
Associated genes
2008
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Marketing authorisation: Eurneffy (EMA)
Regulatory2024-08-22EMA
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
Research2008-03-01The New England journal of medicine
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- 4 industry developments reported.
Upcoming Milestones
- Q4 2026A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges
- Q4 2026Evaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.
- Q1 2027A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
- Q4 2027A Randomized Controlled Study Comparing Virtual Reality-Based Simulation With High-fidelity Simulation for Training Novice Physicians in Emergency Management
- Q3 2028Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Major developments
Upcoming trial readoutHigh impact
Results expected Q3 20282026-09-04
Upcoming trial readoutImportant
Results expected Q1 20272026-06-25
Clinical MilestonesViewHide
Results expected
- 2026-09-04Optimizing the Diagnostic Approach to Cephalosporin Allergy TestingResults expected Q3 2028
- 2026-08-10A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral ChallengesResults expected Q4 2026
- 2026-06-25A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic IndividualsResults expected Q1 2027
- 2026-05-13A Randomized Controlled Study Comparing Virtual Reality-Based Simulation With High-fidelity Simulation for Training Novice Physicians in Emergency ManagementResults expected Q4 2027
- 2026-01-27Evaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.Results expected Q4 2026
Recently completed
- 2025-11-30A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut AllergyPrimary completion
Industry & MarketViewHide
- 2026-10-18Consultation on schools holding Adrenaline Nasal Sprays for anaphylaxisIndustry · MHRA (gov.uk)
- 2026-09-23Elevated ozone activates maternal immunity to drive offspring IgG-mediated anaphylaxis through IgG glycosylation alterationsIndustry · Nature — Environmental Sciences
- 2026-09-16Wales takes UK lead on needle-free anaphylaxis preventionIndustry · pharmaphorum
- 2026-09-03Lipid-Lowering Drugs Tied to Worse Venom AnaphylaxisIndustry · Medscape Medical News
Activity timeline10
- 2026-10-18IndustryConsultation on schools holding Adrenaline Nasal Sprays for anaphylaxisIndustry · MHRA (gov.uk)
- 2026-09-23IndustryElevated ozone activates maternal immunity to drive offspring IgG-mediated anaphylaxis through IgG glycosylation alterationsIndustry · Nature — Environmental Sciences
- 2026-09-16IndustryWales takes UK lead on needle-free anaphylaxis preventionIndustry · pharmaphorum
- 2026-09-04ClinicalOptimizing the Diagnostic Approach to Cephalosporin Allergy TestingResults expected Q3 2028
- 2026-09-03IndustryLipid-Lowering Drugs Tied to Worse Venom AnaphylaxisIndustry · Medscape Medical News
- 2026-08-10ClinicalA Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral ChallengesResults expected Q4 2026
- 2026-06-25ClinicalA First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic IndividualsResults expected Q1 2027
- 2026-05-13ClinicalA Randomized Controlled Study Comparing Virtual Reality-Based Simulation With High-fidelity Simulation for Training Novice Physicians in Emergency ManagementResults expected Q4 2027
- 2026-01-27ClinicalEvaluation of Emergency Medication in Children With Food Allergies: a Prospective, Randomized Clinical Multicenter Study Comparing Antihistamines Versus Antihistamines Plus Steroids in a Controlled Setting of Oral Food Challenges in Children.Results expected Q4 2026
- 2025-11-30ClinicalA Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut AllergyPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Epinephrineapproved
Original application approval — Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due… (2024)
Clinical trials
The current development programme across all trial phases.
Clinical programme
13
6
1
6
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
Product approvals and authorisations
2024emaOriginal application approval — Epinephrine· Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- The New England journal of medicine1
Leading researchers8
- Berlin J1
- Chan E1
- Chung CH1
- Gold D1
- Hatley T1
- Hicklin DJ1
- Hosen J1
- Le QT1
Affiliations (unnormalised)1
- Vanderbilt University School of Medicine1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.